更新于：2024-11-01

CBX1 x CBX5 x CBX3

更新于：2024-11-01

基本信息

关联

项与 CBX1 x CBX5 x CBX3 相关的药物

UNC7047

靶点

CBX1 x CBX3 x CBX5

作用机制

CBX1 inhibitors [+2]

在研机构

The University of North Carolina at Chapel Hill

原研机构

The University of North Carolina at Chapel Hill

在研适应症

诊断试剂

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

UNC-7565

靶点

CBX1 x CBX3 x CBX5

作用机制

CBX1 inhibitors [+2]

在研机构

The University of North Carolina at Chapel Hill

原研机构

The University of North Carolina at Chapel Hill

在研适应症

诊断试剂

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 CBX1 x CBX5 x CBX3 相关的临床结果

登录后查看更多信息

100 项与 CBX1 x CBX5 x CBX3 相关的转化医学

登录后查看更多信息

0 项与 CBX1 x CBX5 x CBX3 相关的专利（医药）

登录后查看更多信息

项与 CBX1 x CBX5 x CBX3 相关的文献（医药）

2023-07-10·BMC cancer

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma.

Article

作者: Liu, Gexiu ; Lu, Peng ; Zhou, Fenling ; Cao, Yuli ; Chen, Lu ; Deng, Cuilan

BACKGROUNDDiffuse large B-cell lymphoma (DLBCL) is one of the most aggressive malignant tumors. Chromobox (CBX) family plays the role of oncogenes in various malignancies.METHODSThe transcriptional and protein levels of CBX family were confirmed by GEPIA, Oncomine, CCLE, and HPA database. Screening of co-expressed genes and gene function enrichment analysis were performed by GeneMANIA and DAVID 6.8. The prognostic value, immune cell infiltration and drug sensitivity analysis of CBX family in DLBCL were performed by Genomicscape, TIMER2.0, and GSCALite database. Confirmatory Tests of CBX family protein expression in DLBCL were performed by immunohistochemistry.RESULTSThe mRNA and protein expressions of CBX1/2/3/5/6 were higher in DLBCL tissues than control groups. Enrichment analysis showed that the functions of CBX family were mainly related to chromatin remodeling, methylation-dependent protein binding, and VEGF signaling pathway. The high mRNA expressions of CBX2/3/5/6 were identified to be associated with short overall survival (OS) in DLBCL patients. Multivariate COX regression indicated that CBX3 was independent prognostic marker. Immune infiltration analysis revealed that the mRNA expressions of CBX family (especially CBX1, CBX5, and CBX6) in DLBCL were significantly correlated with the infiltration of most immune cells (including B cells, CD8 + T cells, CD4 + T cells, neutrophils, monocytes, macrophages, and Treg cells). Meanwhile, there was a strong correlation between the expression levels of CBX1/5/6 and surface markers of immune cells, such as the widely studied PVR-like protein receptor/ligand and PDL-1 immune checkpoint. Notably, our study found that DLBCL cells with CBX1 over-expression were resistant to the common anti-tumor drugs, but CBX2/5 had two polarities. Finally, we confirmed the higher expressions of CBX1/2/3/5/6 in DLBCL tissues compared with control groups by immunohistochemistry.CONCLUSIONWe provided a detailed analysis of the relationship between the CBX family and the prognosis of DLBCL. Distinguished from other studies, We found that high mRNA expressions of CBX2/3/5/6 were associated with poor prognosis in DLBCL patients, and Multivariate COX regression indicated that CBX3 was independent prognostic marker. Besides, our study also found an association between the CBX family and anti-tumour drug resistance, and provided a relationship between CBX family expression and immune cell infiltration.

2023-04-01·Oncology letters

Comprehensive analysis reveals the value of the expression of chromobox family members for bladder urothelial carcinoma prognosis.

Article

作者: Luo, Lianmin ; Liu, Xiaoqiang ; Cao, Runfu ; Wang, Kaihong ; Liu, Yifu ; Zhu, Qiqi ; Fu, Bin ; Jiang, Meichun ; Yang, Chao ; Meng, Xuan ; Zhou, Libo

Bladder urothelial carcinoma (BLCA) accounts for 95% of all cases of bladder cancer worldwide, with a high incidence and poor prognosis. Chromobox (CBX) proteins play a key role in numerous malignant tumors; however, the role of CBX in BLCA remains unknown. Herein, the present study found that, compared with in normal bladder tissues, the expression levels of CBX1, CBX2, CBX3, CBX4 and CBX8 were markedly increased in BLCA tissues, as determined by Tumor Immune Estimation Resource, UALCAN and ONCOMINE analyses, whereas CBX6 and CBX7 were decreased in BLCA tissues. Furthermore, evident hypomethylation in the promoters of CBX1, and CBX2, as well as significant hypermethylation in the promoters of CBX5, CBX6 and CBX7, was detected in BLCA tissues compared with in normal bladder tissues. The expression of CBX1, CBX2 and CBX7 was involved in the prognosis of patients with BLCA. Low CBX7 expression was strongly associated with poorer overall survival in patients with BLCA, whereas high CBX1 and CBX2 expression was associated with poorer progression-free survival. Besides, significant associations were determined between the expression of CBXs and immune cell infiltration, including dendritic cells, neutrophils, macrophages, CD4⁺ T cells, CD8⁺ T cells and B cells. Overall, the current results may provide a rationale for developing new targets and prognostic markers for BLCA therapy.

2021-10-01·Journal of Gastrointestinal Oncology4区 · 医学

Prognostic and immune infiltrates for the Chromobox (CBX) protein family in human pancreatic adenocarcinoma

4区 · 医学

Article

作者: Wu, Daoyuan ; Li, Qian ; Fu, Lei ; Wang, Jufeng

BACKGROUNDGlobally, pancreatic adenocarcinoma (PAAD) is among the most prevalent malignant tumors. The Chromobox (CBX) protein family is a vital component of epigenetic regulatory complexes that have vital biological roles. The biological functions, immune infiltration, expression levels, and the prognostic significance of CBX proteins in PAAD have not yet been established.METHODSUsing bioinformatics tools, such as the Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine, Kaplan-Meier plotter, GeneMANIA, cBioPortal, TIMER and R, we evaluated the prognostic importance, expression levels, gene alterations, risk factors, and immune cell infiltration levels of CBXs in PAAD patients. The expression levels of CBX3 in clinical-pathological samples were also confirmed by immunohistochemistry.RESULTSIn PAAD tissues, CBX1, CBX3, CBX5, and CBX8 expressions were high. High CBX1, CBX5, CBX6, and CBX7 levels were correlated with tumor stages. Elevated CBX2, CBX6, CBX7, and CBX8 messenger ribonucleic acid (mRNA) levels were markedly correlated with better overall survival (OS) outcomes for pancreatic cancer patients, while elevated CBX3 was markedly correlated with short OS outcomes. In particular, we have validated the differential expression of CBX3 on clinical specimens using immunohistochemical methods. A multivariate logistic analysis revealed that elevated mRNA expression levels of CBX3 and suppressed CBX8 levels were independently associated with short OS outcomes for pancreatic cancer patients. The roles of CBXs and their neighboring proteins are associated with a negatively regulated cell cycle, histone binding, polycomb group protein complexes, and the regulation of pluripotent stem cell signaling pathways. Additionally, CBX levels were found to be markedly associated with immune infiltrates, and found that the immune infiltration score of CBX3 was differentially expressed in cell lines such as CD8 T cells, NK cells, Mast cells and T helper cells.CONCLUSIONSCBX3/8 is a potential marker for prognostic outcomes in PAAD patients.